Scientists uncover mutations that make cancer resistant to therapies targeting KRAS

Drugs that inhibit the protein expressed by a mutated form of the KRAS gene might soon be approved, but cancer cells often develop additional mutations that make them resist such targeted drugs. Investigators have identified some of these mutations in a patient and strategies to overcome them.